CNS Pharma
Early Stage
Breakthrough technologies for central nervous system cancers.
Analytics
Raised: $628,558
Aggregate Commitments $
Platform
Republic
Start Date
03/16/2018
Close Date
06/11/2018
Min. Goal
$100,000
Max. Goal
$1,070,000
Min. Investment
$250
Security Type
SAFE
Funding Type
RegCF
Rolling Commitments $
Status
Funded
Reporting Date
06/30/2018
Days Remaining
Funded
% of Min. Goal
629%
% of Max. Goal
59%
Likelihood of Max
Funded
Avg. Daily Raise
$7,225
# of Investors
666
Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Location
Houston, Texas
Industry
Healthcare & Pharmaceuticals
Tech Sector
Glioblastoma Multiforme (GBM) is one of the deadliest forms of brain cancer -- and CNS Pharma wants to do something about it. They’re in the midst of developing Berubicin, a breakthrough drug whose clinical trials have yielded promising results. Berubicin was created at MD Anderson Cancer Center, and it’s the first of its class of drugs to cross the blood brain barrier and reach cancer cells in brain tumor patients. It’s also been granted Orphan Drug status by the US FDA, and CNS expects to start its Phase 2(a) clinical trial soon. CNS has also entered into a collaboration agreement with Reata Pharmaceuticals and plans to list on the NASDAQ in 2018.
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.